Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue: 2012-2019

Historic Non-Current Deffered Revenue for Agios Pharmaceuticals (AGIO) over the last 8 years, with Dec 2019 value amounting to $50.6 million.

  • Agios Pharmaceuticals' Non-Current Deffered Revenue fell 99.05% to $491,000 in Q2 2020 from the same period last year, while for Jun 2020 it was $491,000, marking a year-over-year decrease of 99.05%. This contributed to the annual value of $50.6 million for FY2019, which is 15.43% down from last year.
  • Agios Pharmaceuticals' Non-Current Deffered Revenue amounted to $50.6 million in FY2019, which was down 15.43% from $59.8 million recorded in FY2018.
  • Over the past 5 years, Agios Pharmaceuticals' Non-Current Deffered Revenue peaked at $154.3 million during FY2016, and registered a low of $17.4 million during FY2015.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $59.8 million (2018), whereas its average is $78.7 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Non-Current Deffered Revenue surged by 788.81% in 2016 and then tumbled by 52.46% in 2018.
  • Agios Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $17.4 million in 2015, then surged by 788.81% to $154.3 million in 2016, then declined by 18.47% to $125.8 million in 2017, then crashed by 52.46% to $59.8 million in 2018, then fell by 15.43% to $50.6 million in 2019.